Upcoming updates
for 2026-2027
Pharmacotherapy for Cannabis Use Disorder
Antipsychotic Blood Levels in Practice – Interview
Valproate Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Quick Take Vol. 90
Pharmacological Management of Primary Insomnia
Lithium Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Quick Take Vol. 91
Buspirone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Pharmacotherapy of Alcohol Use Disorder – Interview
Switching Antipsychotics in Clinical Practice 2026 update
Quick Take Vol. 92
Atomoxetine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Antidepressant Withdrawal Effects and Safe Deprescribing – Interview
Pharmacotherapies for Stimulant Use Disorder (Update)
Methylphenidate Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Diagnosis and Management of Generalized Anxiety Disorder: Focus on Treatment-Resistant Cases
Quick Take Vol. 93
Mood and Anxiety Disorders During Perimenopause – Interview
Amphetamines Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Quick Take Vol. 94
Updates on Geriatric Psychopharmacology – Interview
Drug-Drug Interactions in Psychopharmacology.
ADHD Medications: A Comprehensive Formulations Guide
Quick Take Vol. 95
Brexpiprazole Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Psychotropic-Induced Movement Disorders and Cognitive Side Effects (Update) – Interview
Quick Take Vol. 96
Cariprazine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Pharmacotherapy Bipolar Depression: Strategies for Everyday Management – Interview
Lumateperone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
Quick Take Vol. 97
Treatment-Resistant Obsessive-Compulsive Disorder (Update) – Interview
Addiction Psychopharmacology in Patients with Medical Comorbidities – Interview
Management of Psychotropic-Induced Sexual Dysfunction – Interview
CME Info
Médicos – Declaración de acreditación CME
The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.
This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Profesionales de enfermería – Declaración de acreditación CME
The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.
This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
El ANCC acepta los créditos AMA PRA Category 1 Credit(s)™ como horas de contacto, según el siguiente cálculo: 1 CME = 1 hora de contacto..
Asistentes médicos – Declaración de acreditación CME
The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.
This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Autoevaluación para el mantenimiento de la certificación (SA) – Declaración de acreditación
- Psychopharmacology Institute Self-Assessment Program 2026
Dates: April 1, 2026 – April 1, 2029
The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2026 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.
- Psychopharmacology Institute Self-Assessment Program 2025
Dates: April 1, 2025 – April 1, 2028
The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2025 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.
- Psychopharmacology Institute Self-Assessment Program 2024
Dates: April 1, 2024 – April 1, 2027
The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2024 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.